ISSN 2415-3060 (print), ISSN 2522-4972 (online)
  • 27 of 45
Up
JMBS 2021, 6(6): 200–206
https://doi.org/10.26693/jmbs06.06.200
View of a problem

Vaccination against COVID-19 in Ukraine. Safety of Vaccines

Iakovenko N. O., Ogloblina M. V., Nuzhna O. K.
Abstract

COVID-19 is a life-threatening disease that can be asymptomatic in the form of a common ARVI, or in extremely severe forms, with serious long-term consequences. Vaccination against COVID-19 is critically important to restrain the pandemic. The purpose of the study was to analyze and systematize the data of pharmacological supervision of the use of vaccines against COVID-19. For this, methods of analysis, systematization and generalization of information were used using the databases of the State Expert Center of the Ministry of Health of Ukraine, Food and Drug Administration, World Health Organisation in the period from February 24, 2021 to October 31, 2021. Currently, such vaccines are registered and approved for use in Ukraine as AstraZeneca (Covishield, SKBio), Comirnaty / Pfizer-BioNTech, Moderna, CoronaVac / Sinovac Biotech. According to official data, the effectiveness of all these vaccines is quite high. They are especially effective in preventing severe course of disease, hospitalization, and death. Sometimes the vaccination process can be with the development of a number of side effects. Responsibility for the risks associated with the production and use of vaccines dictates the need for constant monitoring of these side effects. That is why we analyzed the data of the State Expert Center of the Ministry of Health of Ukraine about adverse events after immunization from COVID-19 in Ukraine. Thus, the analysis of adverse events reported showed that they took place in 0.018% cases of the total number of vaccine doses that were administered. In the context, for each vaccine separately, the number of adverse events reported were: Covishield – 1128 cases (0.23%), CoronaVac – 419 (0.008%), Comirnaty – 854 (0.02%), AstraZeneca – 540 (0.02%), Moderna – 393 (0.02%), respectively. It should be noted that most of the reported cases of adverse events reported in Ukraine during vaccination against COVID-19 are mild predictable reactions (88.72 – 93.38%). This result allows us to speak of a fairly high predictability of the adverse events reported after COVID-19 vaccination. This is confirmed by the data of world literature. After analyzing the presented data of the State Expert Center of the Ministry of Health of Ukraine, we found that the most of adverse events reported after COVID-19 vaccination are so-called general disorders and disorders at the injection site (fever, fatigue, chills, redness, pain and swelling at the injection site). Neurological disorders ranked second in terms of the number of adverse events reported, and musculoskeletal disorders ranked third. Adverse events reported manifestations from other organs and systems had isolated cases. After using all of the above vaccines, the percentage of adverse events reported was significantly higher in women than in men, which coincides with the data of the world literature. Conclusion. Thus, the analysis of the safety of vaccines against COVID-19, registered and authorized for use in Ukraine, shows that the risks of adverse events reported after COVID-19 vaccination are rare; the most of them are mild and predictable. At the same time, these manifestations of adverse events reported cannot be compared with the health and life risks associated with the COVID-19 disease itself. Ensuring continuous monitoring of the safety of vaccine use and identifying potential side effects will further reduce and manage the risks associated with vaccine use

Keywords: COVID-19, vaccination, adverse events after vaccination

Full text: PDF (Ukr) 284K

References
  1. World Health Organization. Coronavirus disease (COVID-19): Vaccines. Updated October 2021. Available from: https://www.who.int/news-room/questions-and-answers/item/coronavirus-disease-(covid-19)-vaccines
  2. World Health Organization. Coronavirus disease (COVID-19): Vaccines. Updated November 2021. Available from: https://www.who.int/emergencies/diseases/novel-coronavirus-2019
  3. Stowe J, Andrews N, Gower Ch, Gallagher E, Utsi L, Simmons R, et al. Effectiveness of COVID-19 vaccines against hospital admission with the Delta (B.1.617.2) variant. New Engl J Med. 2021 June. Available from: https://khub.net/web/phe-national/public-library/-/document_library/v2WsRK3ZlEig/view_file/479607329?_com_liferay_document_library_web_portlet_DLPortlet_INSTANCE_v2WsRK3ZlEig_redirect=https://khub.net:443/web/phe-national/public-library/-/document_library/v2WsRK3ZlEig/view/479607266
  4. Ministestvo okhorony zdorov’ya Ukrayiny. Use pro vaktsyny vid COVID-19 v Ukrayini [Ministry of Health of Ukraine. All about vaccines from COVID-19 in Ukraine] 2021 Oct. [cited 2021 Oct 28 ]. Available from: https://moz.gov.ua/article/news/use-pro-vakcini-vid-covid-19-v-ukraini-astrazeneca. [Ukrainian]
  5. Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med. 2020 Dec; 383:2603-2615. https://www.ncbi.nlm.nih.gov/pubmed/33301246. PMCID: PMC7745181. https://doi.org/10.1056/NEJMoa2034577
  6. Bernal JL, Andrews N, Gower Ch, Gallagher E, Simmons R, Thelwall S, et al. Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant. N Engl J Med. 2021 Aug;385:585-594. https://www.ncbi.nlm.nih.gov/pubmed/34289274. PMCID: PMC8314739. https://doi.org/10.1056/NEJMoa2108891
  7. Jara Al, Undurraga EA, González C, Paredes F, Fontecilla T, Jara G, et al. Effectiveness of an Inactivated SARS-CoV-2 Vaccine in Chile. N Engl J Med. 2021 Sept;385:875-884. https://www.ncbi.nlm.nih.gov/pubmed/34233097. PMCID: PMC8279092. https://doi.org/10.1056/NEJMoa2107715
  8. Li XN, Huang Y, Wang W, Jing QL, Zhang CH, Qin PZ, et al. Effectiveness of inactivated SARS-CoV-2 vaccines against the Delta variant infection in Guangzhou: a test-negative case–control real-world study. Emerg Microbes Infect. 2021 Dec;10(1):1751-1759. https://www.ncbi.nlm.nih.gov/pubmed/34396940. PMCID: PMC8425710. https://doi.org/10.1080/22221751.2021.1969291
  9. Tang P, Hasan MR, Chemaitelly H, Yassine HM, Benslimane FM, Al Khatib HA, et al. BNT162b2 and mRNA-1273 COVID-19 vaccine effectiveness against the SARS-CoV-2 Delta variant in Qatar. Nat Med. 2021 Nov. https://www.ncbi.nlm.nih.gov/pubmed/34728831. PMCID: PMC8604725. https://doi.org/10.1038/s41591-021-01583-4
  10. Derzhavnyy ekspertnyy tsentr MOZ Ukrayiny. Shchotyzhnevyy zvit pro rezultaty sposterezhennya za bezpekoyu zastosuvannya vaktsyn proty Covid-19 [State Expert Center of the Ministry of Health of Ukraine. Weekly report on the results of safety monitoring of Covid-19 vaccines]. 2021 Available from: https://www.dec.gov.ua/materials/derzhavnyj-ekspertnyj-czentr-moz-ukrayiny-oprylyudnyuye-novyj-shhotyzhnevyj-zvit-pro-rezultaty-sposterezhennya-za-bezpekoyu-zastosuvannya-vakczyn-proty-covid-19-80/# [Ukrainian]
  11. Akau K. Sex and Gender and COVID-19 Vaccine Side Effects. 2021. Available from: https://medicine.yale.edu/news-article/sex-and-gender-and-covid-19-vaccine-side-effects/
  12. Shimabukuro TT, Cole M, Su JR. Reports of Anaphylaxis After Receipt of mRNA COVID-19 Vaccines in the US-December 14, 2020-January 18, 2021. JAMA. 2021 Mar 16;325(11):1101-1102. https://www.ncbi.nlm.nih.gov/pubmed/33576785. https://doi.org/10.1001/jama.2021.1967
  13. Gee J, Marquez P, Su J, Calvert GM, Liu R, Myers T, et al. First Month of COVID-19 Vaccine Safety Monitoring — United States, December 14, 2020–January 13, 2021. MMWR Morb Mortal Wkly Rep. 2021;70:283–288. https://www.ncbi.nlm.nih.gov/pubmed/33630816. PMCID: PMC8344985. https://doi.org/10.15585/mmwr.mm7008e3
  14. Halsey NA, Griffioen M, Dreskin SC, Dekker CL, Wood R, Sharma D, et al. Immediate hypersensitivity reactions following monovalent 2009 pandemic influenza A (H1N1) vaccines: Reports to VAERS. Vaccine. 2013 Dec 9; 31(51): 6107-6112. https://www.ncbi.nlm.nih.gov/pubmed/24120547. https://doi.org/10.1016/j.vaccine.2013.09.066